Author/Authors :
Ayyildiz, Talat Ondokuz Mayis University - Faculty of Medicine - Department of Gastroenterology, Turkey , Aydin, Taner Uludag University - Faculty of Medicine - Department of Internal Medicine, Turkey , Eminler, Ahmet Tarik Uludag University - Faculty of Medicine - Department of Gastroenterology, Turkey , Yildirim, Cinar Uludag University - Faculty of Medicine - Department of Gastroenterology, Turkey , Irak, Kader Uludag University - Faculty of Medicine - Department of Gastroenterology, Turkey , Kiyici, Murat Uludag University - Faculty of Medicine - Department of Gastroenterology, Turkey , Gurel, Selim Uludag University - Faculty of Medicine - Department of Gastroenterology, Turkey , Nak, Selim Giray Uludag University - Faculty of Medicine - Department of Gastroenterology, Turkey , Gulten, Macit Uludag University - Faculty of Medicine - Department of Gastroenterology, Turkey , Dolar, Enver Uludag University - Faculty of Medicine - Department of Gastroenterology, Turkey
Abstract :
Sorafenib is an inhibitor of multikinase proteins which is used for metastaticrenal cell carcinoma and advanced stage hepatocellular carcinoma. Its side effects include serum amylase and lipase elevations anticipated to occur within first weeks of treatment but clinically and radiologically evident acute pancreatitis develops rarely. Five cases of acute pancreatitis have been reported in literature until date. The case we described here is the sixth case of clinically diagnosed acute pancreatitis.
NaturalLanguageKeyword :
Hepatocellular carcinoma , Pancreatitis , Sorafenib , Tyrosine kinase inhibitor
